Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-06-08 | Reverse | 1:20 |
Femasys Inc. develops women’s healthcare solutions, including permanent birth control, artificial insemination, biopsy, and uterine sampling devices, serving OB-GYNs and reproductive professionals globally since 2004.

FemBloc, a non-surgical permanent birth control system by Femasys, has regulatory approval in Europe and is in final U.S. FDA trial phase.
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $336.59K | $719.65K ▲ | $367.33K ▼ | $324.63K ▼ |
![]() | NonUS | $392.8K | $435K ▲ | $57.56K ▼ | $7.2K ▼ |
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
APLM | $27.50 | COMPARE |
HBIO | $7.88 | COMPARE |
BCTX | $3.52 | COMPARE |
COCH | $0.72 | COMPARE |
AIMD | $1.58 | COMPARE |
DARE | $0.77 | COMPARE |
PCSA | $2.08 | COMPARE |
CRIS | $1.38 | COMPARE |